Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

PRIMARY OBJECTIVES: I. To improve the outcomes of patients who have progressed or relapsed lymphoma or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)/prolymphocytic leukemia (PLL) within 180 days following allogeneic hematopoietic cell transplant (HCT) compared to historical data: 12-month overall survival. SECONDARY OBJECTIVES: I. To describe the safety profile observed in these populations. II. Estimate the overall response rate (complete response \[CR\] + partial response \[PR\]) by standard morphologic, flow cytometric, imaging, and molecular techniques. III. Assess progression free-survival. IV. Define incidences of grade III-IV toxicities and infections. V. Estimate incidence of relapse and non-relapse mortality. VI. Estimate incidences of grade II-III and III-IV acute graft-versus-host disease (GVHD) and chronic GVHD. OUTLINE: Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28 or idelalisib PO twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months.